Clinical trial
IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II…
NCT03705403 · Maastricht University Medical Center, Other · Terminated
Key facts
| NCT number | NCT03705403 |
|---|---|
| Title | IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study |
| Official title | Stereotactic Ablative Body Radiotherapy (SABR) Combined with Immunotherapy (L19-IL2) in Stage IV NSCLC Patients, ImmunoSABR: a Multicentre, Randomised Controlled Open-label Phase II Trial |
| Acronym | IMMUNOSABR2 |
| Lead sponsor | Maastricht University Medical Center, Other |
| Collaborators | Academisch Ziekenhuis Maastricht The Netherlands Cancer Institute University Medical Center Nijmegen Erasmus Medical Center University Ghent KU Leuven Centre Oscar Lambret Gasthuis Zusters Antwerpen… |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | NSCLC Stage IV, Metastatic Disease |
| Intervention type | Drug, Radiation |
| Interventions | Darleukin, Radiation |
| Enrollment | 88 |
| Start date | Apr 4, 2019 |
| Primary completion | Jan 6, 2025 |
| Completion | Jan 6, 2025 |
| First posted | Oct 15, 2018 |
| Last update posted | Jan 30, 2025 |
| Countries | Belgium, France, Germany, Italy, Netherlands, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: